Company: SMNR
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001213900-25-044889
Chunk: 1

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
000 shares authorized, 510,000 shares issued and outstanding (excluding 751,837 shares subject to possible redemption as of March 31, 2025 and December 31, 2024, respectively subject to possible redemption) 
     51  
     51 
  
    Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized, 2,062,500 shares issued and outstanding as of March 31, 2025 and December 31, 2024 
     206  
     206 
  
    Accumulated deficit 
     (10,736,738) 
     (10,417,973)
  
    Total shareholders’ deficit 
     (10,736,481) 
     (10,417,716)
  
    Total Liabilities and Shareholders’ Deficit 
    $9,147,903  
    $9,037,873 

The accompanying notes are an integral part of these unaudited condensed financial statements.

1

DENALI CAPITAL ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

    For the  
    For the 

    Three Months  Ended  
    Three Months  Ended 

    March 31,  2025  
    March 31,  2024 

    Formation and operating costs 
    $246,600  
    $368,252 
  
    Loss from operations 
     246,600  
     368,252 

    Other expense/(income) 

    Interest expense 
     26,974  
     21,303 
  
    Income on Trust account 
     (78,971) 
     (653,885)

    Net income/(loss) 
    $(194,603) 
    $264,330 

    Basic and diluted weighted average redeemable ordinary shares outstanding 
     751,837  
     4,537,829 
  
    Basic and diluted net income per redeemable ordinary shares 
    $0.07  
    $0.10 

    Basic and diluted weighted average non-redeemable ordinary shares outstanding 
     2,572,500  
     2,572,500 
  
    Basic and diluted net loss per non-redeemable ordinary share 
    $(0.10) 
    $(0.08)